Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 150

1.

Wolfram Syndrome: A Case Report and Review of Clinical Manifestations, Genetics Pathophysiology, and Potential Therapies.

Toppings NB, McMillan JM, Au PYB, Suchowersky O, Donovan LE.

Case Rep Endocrinol. 2018 Apr 18;2018:9412676. doi: 10.1155/2018/9412676. eCollection 2018.

2.

A Mild PUM1 Mutation Is Associated with Adult-Onset Ataxia, whereas Haploinsufficiency Causes Developmental Delay and Seizures.

Gennarino VA, Palmer EE, McDonell LM, Wang L, Adamski CJ, Koire A, See L, Chen CA, Schaaf CP, Rosenfeld JA, Panzer JA, Moog U, Hao S, Bye A, Kirk EP, Stankiewicz P, Breman AM, McBride A, Kandula T, Dubbs HA, Macintosh R, Cardamone M, Zhu Y, Ying K, Dias KR, Cho MT, Henderson LB, Baskin B, Morris P, Tao J, Cowley MJ, Dinger ME, Roscioli T, Caluseriu O, Suchowersky O, Sachdev RK, Lichtarge O, Tang J, Boycott KM, Holder JL Jr, Zoghbi HY.

Cell. 2018 Feb 22;172(5):924-936.e11. doi: 10.1016/j.cell.2018.02.006.

PMID:
29474920
3.

POLR3A variants in hereditary spastic paraplegia and ataxia.

Gauquelin L, Tétreault M, Thiffault I, Farrow E, Miller N, Yoo B, Bareke E, Yoon G, Suchowersky O, Dupré N, Tarnopolsky M, Brais B, Wolf NI, Majewski J, Rouleau GA, Gan-Or Z, Bernard G.

Brain. 2018 Jan 1;141(1):e1. doi: 10.1093/brain/awx290. No abstract available.

PMID:
29228109
4.

Vascular Parkinsonism in a Tertiary Care Stroke Prevention Clinic and the Development of a New Screening Strategy.

Manosalva HA, Pio F, Jeerakathil T, Saqqur M, Camicioli R, Suchowersky O.

J Stroke Cerebrovasc Dis. 2018 Jan;27(1):153-161. doi: 10.1016/j.jstrokecerebrovasdis.2017.08.020. Epub 2017 Oct 3.

PMID:
28986199
5.

KCNA2 mutations are rare in hereditary spastic paraplegia.

Gan-Or Z, Yoon G, Suchowersky O, Dupré N, Rouleau GA.

Ann Neurol. 2017 Feb;81(2):325-326. doi: 10.1002/ana.24855. No abstract available.

PMID:
28019661
6.

Clinical and genetic study of hereditary spastic paraplegia in Canada.

Chrestian N, Dupré N, Gan-Or Z, Szuto A, Chen S, Venkitachalam A, Brisson JD, Warman-Chardon J, Ahmed S, Ashtiani S, MacDonald H, Mohsin N, Mourabit-Amari K, Provencher P, Boycott KM, Stavropoulos DJ, Dion PA, Ray PN, Suchowersky O, Rouleau GA, Yoon G.

Neurol Genet. 2016 Dec 5;3(1):e122. eCollection 2017 Feb.

7.

A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease.

McGarry A, McDermott M, Kieburtz K, de Blieck EA, Beal F, Marder K, Ross C, Shoulson I, Gilbert P, Mallonee WM, Guttman M, Wojcieszek J, Kumar R, LeDoux MS, Jenkins M, Rosas HD, Nance M, Biglan K, Como P, Dubinsky RM, Shannon KM, O'Suilleabhain P, Chou K, Walker F, Martin W, Wheelock VL, McCusker E, Jankovic J, Singer C, Sanchez-Ramos J, Scott B, Suchowersky O, Factor SA, Higgins DS Jr, Molho E, Revilla F, Caviness JN, Friedman JH, Perlmutter JS, Feigin A, Anderson K, Rodriguez R, McFarland NR, Margolis RL, Farbman ES, Raymond LA, Suski V, Kostyk S, Colcher A, Seeberger L, Epping E, Esmail S, Diaz N, Fung WL, Diamond A, Frank S, Hanna P, Hermanowicz N, Dure LS, Cudkowicz M; Huntington Study Group 2CARE Investigators and Coordinators.

Neurology. 2017 Jan 10;88(2):152-159. doi: 10.1212/WNL.0000000000003478. Epub 2016 Dec 2.

8.

Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia.

Gan-Or Z, Bouslam N, Birouk N, Lissouba A, Chambers DB, Vérièpe J, Androschuk A, Laurent SB, Rochefort D, Spiegelman D, Dionne-Laporte A, Szuto A, Liao M, Figlewicz DA, Bouhouche A, Benomar A, Yahyaoui M, Ouazzani R, Yoon G, Dupré N, Suchowersky O, Bolduc FV, Parker JA, Dion PA, Drapeau P, Rouleau GA, Ouled Amar Bencheikh B.

Am J Hum Genet. 2016 Jun 2;98(6):1271. doi: 10.1016/j.ajhg.2016.05.009. Epub 2016 Jun 2. No abstract available.

9.

Evidence for small fiber neuropathy in early Parkinson's disease.

Podgorny PJ, Suchowersky O, Romanchuk KG, Feasby TE.

Parkinsonism Relat Disord. 2016 Jul;28:94-9. doi: 10.1016/j.parkreldis.2016.04.033. Epub 2016 Apr 28.

PMID:
27160569
10.

Mutations in CAPN1 Cause Autosomal-Recessive Hereditary Spastic Paraplegia.

Gan-Or Z, Bouslam N, Birouk N, Lissouba A, Chambers DB, Vérièpe J, Androschuk A, Laurent SB, Rochefort D, Spiegelman D, Dionne-Laporte A, Szuto A, Liao M, Figlewicz DA, Bouhouche A, Benomar A, Yahyaoui M, Ouazzani R, Yoon G, Dupré N, Suchowersky O, Bolduc FV, Parker JA, Dion PA, Drapeau P, Rouleau GA, Ouled Amar Bencheikh B.

Am J Hum Genet. 2016 May 5;98(5):1038-1046. doi: 10.1016/j.ajhg.2016.04.002. Erratum in: Am J Hum Genet. 2016 Jun 2;98 (6):1271.

11.

Medical Tourism for CCSVI Procedures in People with Multiple Sclerosis: An Observational Study.

Metz LM, Greenfield J, Marrie RA, Jette N, Blevins G, Svenson LW, Alikhani K, Wall W, Dhaliwal R, Suchowersky O.

Can J Neurol Sci. 2016 May;43(3):360-7. doi: 10.1017/cjn.2015.350. Epub 2016 Feb 4.

PMID:
26891024
12.

C9orf 72 Repeat Expansions in Rapid Eye Movement Sleep Disorder.

Venkitachalam A, Hume S, Suchowersky O.

Can J Neurol Sci. 2014 Nov;41(6):681-2. No abstract available.

PMID:
26693538
13.

Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.

JAMA Neurol. 2016 Jan;73(1):102-10. doi: 10.1001/jamaneurol.2015.2736.

PMID:
26569098
14.

Decade in review-movement disorders: tracking the pathogenesis of movement disorders.

Suchowersky O.

Nat Rev Neurol. 2015 Nov;11(11):618-9. doi: 10.1038/nrneurol.2015.201. Epub 2015 Oct 27. No abstract available.

PMID:
26503930
15.

Utility of whole-exome sequencing for those near the end of the diagnostic odyssey: time to address gaps in care.

Sawyer SL, Hartley T, Dyment DA, Beaulieu CL, Schwartzentruber J, Smith A, Bedford HM, Bernard G, Bernier FP, Brais B, Bulman DE, Warman Chardon J, Chitayat D, Deladoëy J, Fernandez BA, Frosk P, Geraghty MT, Gerull B, Gibson W, Gow RM, Graham GE, Green JS, Heon E, Horvath G, Innes AM, Jabado N, Kim RH, Koenekoop RK, Khan A, Lehmann OJ, Mendoza-Londono R, Michaud JL, Nikkel SM, Penney LS, Polychronakos C, Richer J, Rouleau GA, Samuels ME, Siu VM, Suchowersky O, Tarnopolsky MA, Yoon G, Zahir FR; FORGE Canada Consortium; Care4Rare Canada Consortium, Majewski J, Boycott KM.

Clin Genet. 2016 Mar;89(3):275-84. doi: 10.1111/cge.12654. Epub 2015 Sep 22. Review.

16.

Abnormal surround inhibition does not affect asymptomatic limbs in people with cervical dystonia.

McDougall L, Kiernan D, Kiss ZH, Suchowersky O, Welsh TN.

Neurosci Lett. 2015 Sep 14;604:7-11. doi: 10.1016/j.neulet.2015.07.025. Epub 2015 Jul 26.

PMID:
26219986
17.

Sex Differences in Clinical Features of Early, Treated Parkinson's Disease.

Augustine EF, Pérez A, Dhall R, Umeh CC, Videnovic A, Cambi F, Wills AM, Elm JJ, Zweig RM, Shulman LM, Nance MA, Bainbridge J, Suchowersky O.

PLoS One. 2015 Jul 14;10(7):e0133002. doi: 10.1371/journal.pone.0133002. eCollection 2015.

18.

Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results.

Fernandez HH, Standaert DG, Hauser RA, Lang AE, Fung VS, Klostermann F, Lew MF, Odin P, Steiger M, Yakupov EZ, Chouinard S, Suchowersky O, Dubow J, Hall CM, Chatamra K, Robieson WZ, Benesh JA, Espay AJ.

Mov Disord. 2015 Apr;30(4):500-9. doi: 10.1002/mds.26123. Epub 2014 Dec 24.

19.

No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.

Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB Jr, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O.

PLoS One. 2014 Dec 8;9(12):e112287. doi: 10.1371/journal.pone.0112287. eCollection 2014.

20.

Novel SACS Mutation Deviates from the French Canadian ARSACS Phenotype.

McKenzie ED, Sharma PN, Parboosingh JS; Forge Canada Consortium, Suchowersky O.

Can J Neurol Sci. 2014 Jan;41(1):88-9. No abstract available.

PMID:
26693535
21.

Exome sequencing as a diagnostic tool for pediatric-onset ataxia.

Sawyer SL, Schwartzentruber J, Beaulieu CL, Dyment D, Smith A, Warman Chardon J, Yoon G, Rouleau GA, Suchowersky O, Siu V, Murphy L, Hegele RA, Marshall CR; FORGE Canada Consortium, Bulman DE, Majewski J, Tarnopolsky M, Boycott KM.

Hum Mutat. 2014 Jan;35(1):45-9.

22.

Recessive TRAPPC11 mutations cause a disease spectrum of limb girdle muscular dystrophy and myopathy with movement disorder and intellectual disability.

Bögershausen N, Shahrzad N, Chong JX, von Kleist-Retzow JC, Stanga D, Li Y, Bernier FP, Loucks CM, Wirth R, Puffenberger EG, Hegele RA, Schreml J, Lapointe G, Keupp K, Brett CL, Anderson R, Hahn A, Innes AM, Suchowersky O, Mets MB, Nürnberg G, McLeod DR, Thiele H, Waggoner D, Altmüller J, Boycott KM, Schoser B, Nürnberg P, Ober C, Heller R, Parboosingh JS, Wollnik B, Sacher M, Lamont RE.

Am J Hum Genet. 2013 Jul 11;93(1):181-90. doi: 10.1016/j.ajhg.2013.05.028. Epub 2013 Jul 3.

23.

Mutations in BICD2, which encodes a golgin and important motor adaptor, cause congenital autosomal-dominant spinal muscular atrophy.

Neveling K, Martinez-Carrera LA, Hölker I, Heister A, Verrips A, Hosseini-Barkooie SM, Gilissen C, Vermeer S, Pennings M, Meijer R, te Riele M, Frijns CJ, Suchowersky O, MacLaren L, Rudnik-Schöneborn S, Sinke RJ, Zerres K, Lowry RB, Lemmink HH, Garbes L, Veltman JA, Schelhaas HJ, Scheffer H, Wirth B.

Am J Hum Genet. 2013 Jun 6;92(6):946-54. doi: 10.1016/j.ajhg.2013.04.011. Epub 2013 May 9.

24.

Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onset.

Ramos EM, Latourelle JC, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Gellera C, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME.

Neurogenetics. 2013 Nov;14(3-4):173-9. doi: 10.1007/s10048-013-0364-y. Epub 2013 May 4.

25.

Degradation of stored movement representations in the Parkinsonian brain and the impact of levodopa.

D'Andrea JN, Haffenden AM, Furtado S, Suchowersky O, Goodyear BG.

Neuropsychologia. 2013 Jun;51(7):1195-203. doi: 10.1016/j.neuropsychologia.2013.04.003. Epub 2013 Apr 13.

PMID:
23591046
26.

Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Suchowersky O, Armstrong MJ, Miyasaki J.

Neurology. 2013 Mar 5;80(10):970. doi: 10.1212/WNL.0b013e3182885eb3. No abstract available.

PMID:
23460621
27.

Obstacle Avoidance amongst Parkinson Disease Patients Is Challenged in a Threatening Context.

Doan JB, de Bruin N, Pellis SM, Suchowersky O, Whishaw IQ, Brown LA.

J Neurodegener Dis. 2013;2013:787861. doi: 10.1155/2013/787861. Epub 2013 May 15.

28.

Non-motor symptoms and parkinsonism.

Suchowersky O.

Can J Neurol Sci. 2013 Jan;40(1):1-2. No abstract available.

PMID:
23250119
29.

Canadian Guidelines on Parkinson's Disease.

Grimes D, Gordon J, Snelgrove B, Lim-Carter I, Fon E, Martin W, Wieler M, Suchowersky O, Rajput A, Lafontaine AL, Stoessl J, Moro E, Schoffer K, Miyasaki J, Hobson D, Mahmoudi M, Fox S, Postuma R, Kumar H, Jog M; Canadian Nourological Sciences Federation.

Can J Neurol Sci. 2012 Jul;39(4 Suppl 4):S1-30. No abstract available.

PMID:
23126020
30.

Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset.

Ramos EM, Latourelle JC, Lee JH, Gillis T, Mysore JS, Squitieri F, Di Pardo A, Di Donato S, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Marder K, Gusella JF, Lee JM, Alonso I, Sequeiros J, Myers RH, Macdonald ME.

Hum Genet. 2012 Dec;131(12):1833-40. doi: 10.1007/s00439-012-1205-z. Epub 2012 Jul 25.

31.

TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Lee JH, Lee JM, Ramos EM, Gillis T, Mysore JS, Kishikawa S, Hadzi T, Hendricks AE, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Gellera C, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Landwehrmeyer GB; Registry Study of the European Huntington's Disease Network, Shoulson I; Huntington Study Group COHORT project, Myers RH, MacDonald ME, Gusella JF.

Biochem Biophys Res Commun. 2012 Aug 3;424(3):404-8. Epub 2012 Jul 3.

32.

Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region.

Lee JM, Gillis T, Mysore JS, Ramos EM, Myers RH, Hayden MR, Morrison PJ, Nance M, Ross CA, Margolis RL, Squitieri F, Griguoli A, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, MacDonald ME, Gusella JF.

Am J Hum Genet. 2012 Mar 9;90(3):434-44. doi: 10.1016/j.ajhg.2012.01.005. Epub 2012 Mar 1.

33.

Increased intestinal permeability and Parkinson disease patients: chicken or egg?

Salat-Foix D, Tran K, Ranawaya R, Meddings J, Suchowersky O.

Can J Neurol Sci. 2012 Mar;39(2):185-8.

PMID:
22343151
34.

CAG repeat expansion in Huntington disease determines age at onset in a fully dominant fashion.

Lee JM, Ramos EM, Lee JH, Gillis T, Mysore JS, Hayden MR, Warby SC, Morrison P, Nance M, Ross CA, Margolis RL, Squitieri F, Orobello S, Di Donato S, Gomez-Tortosa E, Ayuso C, Suchowersky O, Trent RJ, McCusker E, Novelletto A, Frontali M, Jones R, Ashizawa T, Frank S, Saint-Hilaire MH, Hersch SM, Rosas HD, Lucente D, Harrison MB, Zanko A, Abramson RK, Marder K, Sequeiros J, Paulsen JS; PREDICT-HD study of the Huntington Study Group (HSG), Landwehrmeyer GB; REGISTRY study of the European Huntington's Disease Network, Myers RH; HD-MAPS Study Group, MacDonald ME, Gusella JF; COHORT study of the HSG.

Neurology. 2012 Mar 6;78(10):690-5. doi: 10.1212/WNL.0b013e318249f683. Epub 2012 Feb 8.

35.

The management of gastrointestinal symptoms in Parkinson's disease.

Salat-Foix D, Suchowersky O.

Expert Rev Neurother. 2012 Feb;12(2):239-48. doi: 10.1586/ern.11.192. Review.

PMID:
22288679
36.

Can Alberta's primary care networks provide any lessons for Medicare Locals?

Suchowersky A, Suchowersky O, Duckett SJ.

Med J Aust. 2012 Jan 16;196(1):27-8.

PMID:
22256923
37.

Gastrointestinal symptoms in Parkinson disease: clinical aspects and management.

Salat-Foix D, Andrews CN, Meddings J, Suchowersky O.

Can J Neurol Sci. 2011 Jul;38(4):557-64. Review.

PMID:
21672695
38.

Tauopathies: one disease or many?

Bouchard M, Suchowersky O.

Can J Neurol Sci. 2011 Jul;38(4):547-56. Review.

PMID:
21672694
39.

Hospitalization in Parkinson disease: a survey of National Parkinson Foundation Centers.

Chou KL, Zamudio J, Schmidt P, Price CC, Parashos SA, Bloem BR, Lyons KE, Christine CW, Pahwa R, Bodis-Wollner I, Oertel WH, Suchowersky O, Aminoff MJ, Malaty IA, Friedman JH, Okun MS.

Parkinsonism Relat Disord. 2011 Jul;17(6):440-5. doi: 10.1016/j.parkreldis.2011.03.002. Epub 2011 Apr 1.

40.

Management of the hospitalized patient with Parkinson's disease: current state of the field and need for guidelines.

Aminoff MJ, Christine CW, Friedman JH, Chou KL, Lyons KE, Pahwa R, Bloem BR, Parashos SA, Price CC, Malaty IA, Iansek R, Bodis-Wollner I, Suchowersky O, Oertel WH, Zamudio J, Oberdorf J, Schmidt P, Okun MS; National Parkinson Foundation Working Group on Hospitalization in Parkinson's Disease.

Parkinsonism Relat Disord. 2011 Mar;17(3):139-45. doi: 10.1016/j.parkreldis.2010.11.009. Epub 2010 Dec 14. Review.

41.

Adult cases of congenital muscular torticollis successfully treated with botulinum toxin.

Bouchard M, Chouinard S, Suchowersky O.

Mov Disord. 2010 Oct 30;25(14):2453-6. doi: 10.1002/mds.23371.

PMID:
20976740
42.

Walking with music is a safe and viable tool for gait training in Parkinson's disease: the effect of a 13-week feasibility study on single and dual task walking.

de Bruin N, Doan JB, Turnbull G, Suchowersky O, Bonfield S, Hu B, Brown LA.

Parkinsons Dis. 2010 Jul 13;2010:483530. doi: 10.4061/2010/483530.

43.

Outcomes of patients with Parkinson disease and pathological gambling.

Bharmal A, Lu C, Quickfall J, Crockford D, Suchowersky O.

Can J Neurol Sci. 2010 Jul;37(4):473-7.

PMID:
20724254
44.

Obstacle crossing among people with Parkinson disease is influenced by concurrent music.

Brown LA, de Bruin N, Doan J, Suchowersky O, Hu B.

J Rehabil Res Dev. 2010;47(3):225-31.

45.

Attention and reach-to-grasp movements in Parkinson's disease.

Lu C, Bharmal A, Kiss ZH, Suchowersky O, Haffenden AM.

Exp Brain Res. 2010 Aug;205(1):69-80. doi: 10.1007/s00221-010-2341-0. Epub 2010 Jun 29.

PMID:
20585762
46.

Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease.

Toth C, Breithaupt K, Ge S, Duan Y, Terris JM, Thiessen A, Wiebe S, Zochodne DW, Suchowersky O.

Ann Neurol. 2010 Jul;68(1):28-36. doi: 10.1002/ana.22021.

PMID:
20582991
47.

Challenging context affects standing reach kinematics among Parkinson's disease patients.

Doan JB, Whishaw IQ, Pellis SM, Suchowersky O, de Bruin N, Brown LA.

Behav Brain Res. 2010 Dec 6;214(1):135-41. doi: 10.1016/j.bbr.2010.05.006. Epub 2010 May 15.

PMID:
20478337
48.

Neuronal Intranuclear Inclusion Disease presenting as juvenile Parkinsonism.

Wiltshire KM, Dunham C, Reid S, Auer RN, Suchowersky O.

Can J Neurol Sci. 2010 Mar;37(2):213-8.

PMID:
20437931
49.

Reply: neuropathy as a potential complication of levodopa use in Parkinson's disease: a pharmacological and pharmacovigilance point of view.

Toth C, Suchowersky O, Zochodne D.

Mov Disord. 2010 Mar 15;25(4):525. doi: 10.1002/mds.22879. No abstract available.

PMID:
20155864
50.

Impact of belief in neuroprotection on therapeutic intervention in Parkinson's disease.

Elble RJ, Suchowersky O, Shaftman S, Weiner WJ, Huang P, Tilley B; NINDS NET-PD Investigators.

Mov Disord. 2010 Jun 15;25(8):1082-6. doi: 10.1002/mds.22997.

Supplemental Content

Loading ...
Support Center